drosophila
melanogast
first
step
steppingston
antiinfect
ilia
tzelepi
stefaniaelisavet
kapsetaki
stavria
panayid
yiorgo
apidianaki
follow
expans
antibiot
drug
discoveri
previou
centuri
face
bottleneck
product
new
antiinfect
drug
tradit
chemic
librari
screen
either
use
vitro
cultur
system
silico
identifi
chemic
modifi
small
molecul
antimicrobi
properti
nevertheless
almost
compound
pass
vitro
screen
fail
pass
preclin
trial
drug
screen
drosophila
offer
fill
gap
vitro
mammalian
model
host
test
elimin
compound
toxic
reduc
bioavail
identifi
other
may
boost
innat
host
defenc
select
reduc
microbi
virul
wholeorgan
set
altern
screen
method
drosophila
lowthroughput
may
reduc
cost
increas
success
rate
preclin
trial
common
countermeasur
evergrow
antibiot
drug
resist
product
new
effect
drug
nevertheless
rate
product
new
antibiot
steadili
declin
one
reason
might
chemic
screen
method
reli
sole
vitro
cultur
system
tradit
drug
research
move
vitro
small
molecul
screen
preclin
assess
mammalian
host
two
problem
approach
first
test
mammal
costli
usual
restrict
compound
time
second
vitro
assay
inappropri
captur
complex
infect
host
live
host
prefer
enabl
drug
toxic
bioavail
assess
organism
level
addit
drug
might
interfer
host
microenviron
microbi
virul
per
se
assess
upon
interact
microb
host
thu
qualiti
antiinfect
drug
assess
simpl
model
host
might
effect
way
identifi
new
drug
lead
review
aim
examin
suitabl
drosophila
melanogast
model
organ
antiinfect
drug
assess
due
high
degre
molecular
cellular
physiolog
conserv
human
allow
model
infect
recapitul
aspect
human
diseas
respect
drosophila
might
fill
gap
vitro
screen
preclin
trial
use
directli
instead
vitro
screen
drosophila
short
life
cycl
day
egg
sexual
matur
adult
compar
month
mice
tabl
larg
number
fli
propag
quickli
sinc
ten
femal
produc
hundr
offspr
within
two
week
offspr
becom
sexual
matur
earli
adult
life
enabl
life
cycl
continu
due
small
size
mm
length
thousand
fli
contain
space
would
normal
fit
less
mice
addit
fli
food
usual
made
groceri
store
ingredi
cornmeal
yeast
sucros
thu
cost
mainten
quit
low
moreov
ethic
concern
regul
protocol
use
biomed
research
advantag
caenorhabd
elegan
popular
invertebr
model
host
drug
mix
fli
food
also
administ
inject
tabl
precis
dose
nl
drug
solut
customarili
inject
fli
less
ml
paper
disc
suffic
feed
fli
hour
henc
small
quantiti
drug
requir
experi
yet
anoth
reason
drug
test
fli
expens
addit
drosophila
use
toxicolog
studi
rel
toxic
chemic
fli
correl
well
mammal
final
drosophila
infect
inflamm
easili
studi
relat
age
overcom
barrier
long
experiment
time
drosophila
maximum
life
span
rang
day
day
fli
roughli
correspond
year
human
fli
exhibit
age
effect
earli
day
post
onset
adulthood
drosophila
long
histori
model
organ
genet
signific
similar
human
term
gene
homolog
function
homolog
human
diseas
relat
gene
invertebr
model
host
studi
today
tabl
genom
fulli
sequenc
one
bestannot
among
eukaryot
thu
mani
technolog
develop
techniqu
easili
commonli
use
transgenesi
rna
interfer
rnai
technolog
gene
microarray
doublestrand
rna
synthes
almost
gene
tool
commerci
avail
condit
inactiv
essenti
gene
interest
vivo
cell
cultur
exampl
drosophila
cell
use
genomewid
rnai
screen
rapidli
identifi
gene
requir
replic
influenza
dengu
virus
furthermor
larg
collect
mutant
transgen
drosophila
stock
maintain
bloomington
stock
center
around
world
http
flybaseorg
moreov
drosophila
genom
contain
fewer
gene
human
consequ
present
less
overal
genet
redund
allow
easier
target
identif
although
multipl
modifi
drug
might
need
mammal
affect
multipl
gene
variant
final
varieti
genet
tool
marker
avail
today
order
studi
role
microbi
pathogen
tissuespecif
use
system
advantag
model
host
express
drosophila
gene
control
time
tissuespecif
tabl
exampl
tissuespecif
tempor
rnai
allow
identif
jak
stat
signal
pathway
regul
intestin
immun
respons
regener
fruit
fli
addit
intestin
damag
regener
studi
flipout
clone
cell
eman
intestin
stem
cell
well
mitot
clone
use
either
bgalactosidas
marker
mosaic
analysi
repress
cell
marker
method
drosophila
physiolog
immun
system
conserv
signific
mammalian
research
sever
organ
specif
cell
fundament
immun
respons
highli
conserv
fli
mammal
signific
advantag
invertebr
model
host
studi
today
tabl
fli
defin
brain
interact
organ
exampl
fat
bodi
intestin
via
cytokin
insulin
peptid
respect
fat
bodi
equival
mammalian
liver
innat
immun
metabol
organ
fli
intestin
bear
mani
similar
mammal
term
cellular
molecular
biolog
epitheli
architectur
plasmatocyt
macrophagelik
cell
drosophila
detect
phagocytos
microb
secret
cytokin
antimicrobi
peptid
muscl
cell
drosophila
flight
muscl
heart
intestin
stratifi
smooth
similarli
human
share
role
host
respons
infect
drosophila
trachea
airtransport
organ
similar
human
vasculatur
final
nephrocyt
malpighian
tubul
kidneylik
cell
role
host
defenc
drosophila
epithelia
attach
cuticl
well
intestin
trachea
physic
barrier
pathogen
invas
first
respond
extern
microb
microb
invad
antiinfect
epithelia
local
tissu
drosophila
flight
muscl
respond
wound
infect
elicit
local
host
defenc
respons
orchestr
highli
conserv
jnk
pathway
importantli
muscl
respons
wound
infect
appear
conserv
mice
human
hand
bacteria
enter
damag
intestin
induc
enterocyt
regener
serv
defenc
respons
protect
host
numer
conserv
signal
pathway
involv
intestin
regener
upon
infect
includ
wntwg
notch
hippo
jnk
insrinr
jakstat
nfkb
pathway
case
microb
pass
intestin
barrier
epithelia
addit
mechan
protect
take
place
includ
phagocytosi
plasmatocyt
analog
mammalian
macrophag
product
antimicrobi
peptid
fat
bodi
mani
bacteria
fungi
induc
toll
andor
immun
defici
imd
pathway
two
highli
conserv
nfkb
pathway
system
drosophila
immun
respons
viral
infect
elicit
system
immun
respons
via
univers
conserv
rnai
mechan
drosophila
small
interf
rna
pathway
activ
doublestrand
viral
rna
dna
moreov
dexdh
box
helicas
cell
autophagi
well
conserv
jakstat
imdtnf
andor
tolltlr
innat
immun
cascad
play
crucial
role
respond
viral
rna
fli
mammal
mani
human
bacteri
pathogen
studi
drosophila
includ
gramposit
bacteria
enterococcu
faecali
staphylococcu
aureu
steptococcu
pneumonia
bacillu
cereu
listeria
monocytogen
gramneg
bacteria
vibrio
cholera
serratia
marcescen
pseudomona
aeruginosa
salmonella
typhimurium
chlamydia
spp
burkholderia
cepacia
yersinia
pseudotuberculosi
francisella
tularensi
legionella
pneumophila
mycobacterium
marinum
p
aeruginosa
marinum
may
suppress
innat
immun
respons
part
virul
repertoir
interestingli
antibiot
rifampicin
dinitrobenzamid
amikacin
isoniazid
show
good
bioavail
fed
fli
allevi
system
marinum
infect
special
note
success
antituberculosi
drug
isoniazid
pyrazinamid
tuberculosi
model
microb
marinum
facilit
boost
host
cell
autophagi
fli
mammal
data
suggest
direct
antibacteri
efficaci
also
innat
immun
induct
share
similar
fli
mammal
exploit
pharmacolog
assess
fli
intestin
p
aeruginosa
induc
damag
apoptosi
midgut
enterocyt
drosophila
turn
induc
intestin
stem
cell
prolifer
process
howev
revers
upon
bacteria
clearanc
common
food
preserv
methyl
paraben
propion
acid
strikingli
oncogen
express
drosophila
hindgut
cell
induc
tumor
delamin
basal
side
epithelium
upon
p
aeruginosa
infect
addit
process
inhibit
elimin
infect
use
food
preserv
furthermor
small
chemic
produc
p
aeruginosa
shown
reduc
p
aeruginosa
virul
drosophila
mice
final
research
exploit
phage
antiinfect
p
aeruginosa
use
drosophila
fruit
fli
infect
p
aeruginosa
treat
bacteriophag
feed
find
encourag
futur
assess
food
preserv
natur
biolog
product
includ
bacteri
metabolit
bacteriophag
antiinfect
apart
bacteria
human
fungal
pathogen
also
inflict
diseas
fli
candida
albican
aspergillu
fumigatu
aspergillu
hypha
cryptococcu
neoforman
cunninghamella
berthollethia
scedosporium
spp
fusarium
spp
studi
fli
zygomycet
c
berthollethia
meticul
studi
combin
chemic
modifi
iron
drosophila
enhanc
zygomycet
virul
tradit
use
human
corticosteroid
increas
iron
suppli
iron
avail
treatment
deferoxamin
dramat
increas
pathogen
zygomycet
accordingli
iron
starvat
induc
treatment
iron
chelat
deferasirox
significantli
protect
infect
fli
anoth
common
antifung
voriconazol
potent
f
moniliform
apiopermum
infect
fli
moreov
combinatori
drug
assess
assay
drosophila
reveal
synerg
voriconazol
terbinafin
aspergillu
fumigatu
similar
seen
mammal
recent
anoth
synergi
shown
tarcolimu
posaconazon
fli
mice
ryzopu
oryza
aforement
treatment
administ
feed
fli
infect
either
superfici
system
mani
antifung
drug
appropri
human
may
good
bioavail
efficaci
fli
last
three
also
studi
adult
fli
thu
allow
assess
treatment
whole
organ
set
pertin
identif
gene
target
virus
drosophila
nramp
human
homologu
identifi
necessari
entri
sindbi
viru
host
cell
addit
drosophila
identifi
similar
mammalian
ortholog
import
host
defenc
infect
vesicular
stomat
viru
via
induct
cell
autophagi
final
west
nile
viru
regionderiv
rna
molecul
known
subgenom
flaviviru
rna
suppress
sirnainduc
mirnainduc
rnai
pathway
mammalian
insect
cell
indic
rnaibas
therapi
might
goal
near
futur
insectborn
flavivirus
despit
numer
advantag
melanogast
model
organ
studi
antiinfect
also
sever
shortcom
fli
infect
maintain
temperatur
problem
studi
pathogen
virul
factor
requir
mammalian
bodi
temperatur
also
inabl
simul
human
intestin
anaerob
microflora
disadvantag
microaerophil
aerotoler
bacteria
might
use
infect
fli
presenc
oxygen
fli
intestin
prohibit
fli
infect
strict
anaerob
plenti
human
gut
nevertheless
microb
difficult
establish
infect
specif
virul
factor
express
administ
fli
studi
virul
moreov
pharmacokinet
analys
still
problemat
insect
precis
method
measur
level
administ
drug
tissuespecif
insect
xenobiot
metabol
might
differ
mammal
furthermor
oppos
mammal
drosophila
lack
adapt
immun
system
special
immun
respons
cell
dendrit
cell
dc
b
lymphocyt
respons
immunolog
specif
memori
addit
despit
signific
conserv
core
drosophila
signal
pathway
might
activ
differ
fli
mammal
exampl
mammalian
tolltlr
pathway
directli
activ
microbi
associ
molecular
pattern
drosophila
toll
activ
indirectli
cascad
proteas
mammalian
local
intracellular
membran
versu
plasma
membraneloc
drosophila
final
highthroughput
screen
antiinfect
develop
drosophila
major
drawback
compar
invertebr
host
tabl
recent
year
convent
method
use
pharmacolog
studi
discoveri
new
therapeut
drug
base
either
screen
small
molecul
librari
capac
induc
specif
phenotyp
vitro
silico
howev
efficaci
method
low
lack
complex
dynam
hostpathogen
interact
occur
vivo
consequ
use
mammalian
host
studi
need
seem
widespread
preval
nowaday
even
use
convent
anim
model
purpos
timeconsum
labori
expens
mention
ethic
concern
exploit
altern
strategi
melanogast
promis
use
host
may
cover
gap
comput
cellular
test
studi
test
mammal
figur
lowthroughput
drug
assess
drosophila
proven
meaning
largescal
assess
might
also
possibl
basi
protocol
use
identif
molecul
modifi
diseas
progress
fragil
x
syndrom
though
screen
compound
fli
screen
small
molecul
identifi
reserpin
sleep
regul
addit
fli
use
assess
drug
alreadi
approv
human
use
figur
inde
efficaci
number
licens
antiinfect
agent
evalu
drosophila
demonstr
signific
correl
drug
efficaci
fli
mammal
therefor
use
drosophila
antiinfect
drug
discoveri
may
promis
auxiliari
tool
preclin
research
drosophila
use
either
valid
candid
drug
combinatori
drug
assess
assay
identifi
synergist
drug
combin
fli
signific
similar
human
enabl
facil
cost
effect
assess
antiinfect
drug
interact
microb
host
hit
select
vitro
silico
chemic
screen
screen
drosophila
surviv
microbi
colon
assay
select
drug
candid
higher
success
rate
preclin
trial
addit
natur
product
exampl
microbi
secondari
metabolit
drug
approv
human
test
fist
time
combinatori
fli
identifi
synergist
effect
two
chemic
